Hot Biotech Movers: VIVUS (NASDAQ:VVUS), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA)

VIVUS Inc (NASDAQ:VVUS) will be announcing its Q114 earnings results on Monday, May 5th. Analysts expect the company to announce earnings of ($0.37) per share and revenue of $11.40 million for the quarter. VIVUS, Inc. (NASDAQ:VVUS) stock performance was -2.12% in last session and finished the day at $5.09. Traded volume was 1.34million shares in the last session and the average volume of the stock … Continue reading Hot Biotech Movers: VIVUS (NASDAQ:VVUS), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA)

Healthcare Watch List: Arena Pharmaceuticals (NASDAQ:ARNA), Abbott Laboratories (NYSE:ABT), UnitedHealth Group (NYSE:UNH), AstraZeneca (NYSE:AZN)

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported that Eisai Inc. has launched a national television advertising campaign for BELVIQ® (lorcaserin HCl), an FDA-approved prescription treatment for chronic weight management. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock performance was 0.32% in last session and finished the day at $6.20. Traded volume was 4.92million shares in the last session and the average volume of the stock remained 5.60million shares. The beta … Continue reading Healthcare Watch List: Arena Pharmaceuticals (NASDAQ:ARNA), Abbott Laboratories (NYSE:ABT), UnitedHealth Group (NYSE:UNH), AstraZeneca (NYSE:AZN)

JPMorgan Chase & Co. (NYSE:JPM) EVP Gordon Smith sold 71,952 shares of the stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $54.91, for a total value of $3,950,884.32. Following the transaction, the executive vice president now directly owns 143,905 shares of the company’s stock, valued at approximately $7,901,824. JPMorgan Chase & Co. (NYSE:JPM) stock … Continue reading Recent Insider Selling: JPMorgan Chase (NYSE:JPM), Micron Technology (NASDAQ:MU), Gilead Sciences (NASDAQ:GILD), Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals Inc (NASDAQ:ARNA) Director Tina Susan Nova sold 35,000 shares of the stock on the open market in a transaction dated Monday, April 14th. The shares were sold at an average price of $6.22, for a total value of $217,700.00. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock performance was 3.25% in last session and finished the day at $6.35. Traded volume was 6.98million shares in the … Continue reading Small Cap Recent Insider Selling: Arena Pharmaceuticals (NASDAQ:ARNA), Zeltiq Aesthetics (NASDAQ:ZLTQ), Entravision Communication (NYSE:EVC), RetailMeNot Inc (NASDAQ:SALE)

Sales of the Arena Pharmaceuticals Inc (NASDAQ:ARNA) anti-obesity drug Belviq have closed out the quarter on a positive note. Sales improved throughout the quarter and are pacing well ahead of the previous quarter. Though this week’s sales only take us to March 28th, there is enough here for us to assess the sales activity, project some revenue, and look to the pace. Arena Pharmaceuticals, Inc. … Continue reading Biotech Active runners: Arena Pharmaceuticals (NASDAQ:ARNA), Halozyme Therapeutics (NASDAQ:HALO), Gildan Activewear (NYSE:GIL), Ariad Pharmaceuticals (NASDAQ:ARIA)

Gilead Sciences, Inc. (NASDAQ:GILD) was active yesterday as one Bloomberg reporter thinks he has another take on the recent Waxman letter. Drew Armstrong — via his own Twitter account — said Gilead execs had a meeting scheduled with Waxman all along and the letter just seemed like Waxman was making an effort to drag them in. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 3.37% in … Continue reading Biotech Most Active Stocks: Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)